Publication Topic

Jensen IS, Wu C, Fan W, Lodise T, Nicolau, DP, DuFour S, Cyr PL, et al. 2016. Use of oritivancin in moderate-severe ABSSSI patients requiring IV antibiotics: US hospital budget impact analysis. J Manag Care Spec Pharm 22(6):752-64; doi: 10.18553/jmcp.2016.22.6.752.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8.

Sacks NC, Cabral HJ, Pizer SD, Burgess JF. 2016. Myopic and forward looking behavior in branded oral anti-diabetic consumption: An example from Medicare Part D. Health Econ, May.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

Katz AJ, Chia VM, Schoonen WM, Kelsh MA. 2015. Acute lymphoblastic leukemia: An assessment of international incidence, survival, and disease burden. Cancer Causes Control 26(11):1627–1642.

Sacks NC, Ash AS, Ghosh K, Rosen AK, Wong JB, Cutler DM, Rosen AB. 2015. Recent national trends in acute myocardial infarction hospitalizations in Medicare: Shrinking declines and growing disparities [Letter to the Editor]. Epidemiol 26(4):e46–47; doi: 10.1097/EDE.0000000000000298.

Lancet JE, Cyr PL, Sacks NC, Chiarella MT, Louie AC, Cortes JE. CPX-351 enables administration of consolidation treatment in the outpatient setting and increases the time spent out of the hospital after completion of AML treatment compared with 7+3. American Society of Hematology Annual Meeting, San Diego CA, 2015.

Chia VM, O’Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, et al. 2013. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol 129(2):346–352. doi: 10.1016/j.ygyno.2013.02.014.

Lowe KA, Chia VM, Taylor A, O’Malley C, Kelsh M, Mohamed M, et al. 2013. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 130(1): 107–114.

Olchanski N, McInnis-Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH. 2013. The economic burden of treatment-resistant depression. Clin Ther 35(4):512-522; doi: 10.1016/j.clinthera.2012.09.001.